RESUMEN
PURPOSE: To review the efficacy and safety of oral vismodegib (Erivedge; Genentech) in the management of locally advanced orbital and periorbital basal cell carcinoma (BCC). METHODS: A literature search was conducted last in September 2023 in the PubMed database for English language original research that evaluated the effect of oral vismodegib on orbital and periorbital BCC. Sixty articles were identified and 16 met the inclusion criteria. RESULTS: Most studies demonstrated high response rates, with up to 100% of patients responding to the medication in individual studies and initial complete regression occurring in up to 88% of patients. Vismodegib treatment resulted in significant reductions in tumor volume, resulting in globe preservation for most patients. However, in 12% of patients, the response was partial. Recurrences also occurred with substantial frequency, even after an initial complete response. As such, up to 79.4% of patients required surgical intervention, and up to 23% of patients still required exenteration. Use of these agents resulted in reductions in tumor volume that may delay or prevent the need for exenteration in some, but not all, patients. Importantly, molecular analysis of tissue excised after vismodegib therapy revealed persistent tumor in all patients, with frequent accumulation of mutations that may confer resistance to further hedgehog inhibitor therapy. Although most adverse events were rated as level I or II, side effects were common, with up to 100% of patients in studies experiencing at least 1 event. Muscle cramps, alopecia, weight loss, fatigue, and dysgeusia were the most common adverse events, and several patients discontinued therapy because of them. Furthermore, 1 patient died of sepsis that may have resulted from the therapy. CONCLUSIONS: Although level I and II evidence are lacking, most studies indicate a benefit from the use of oral vismodegib to treat orbital and periorbital BCC tumor volume. However, patients should be cautioned about the adverse side effects of treatment and the persistence of tumor cells with mutations that may cause long-term resistance. Use of vismodegib as short-term neoadjuvant therapy may be effective in shrinking tumor volume to reduce surgical morbidity while reducing the frequency and severity of side effects. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
RESUMEN
PURPOSE: To review the efficacy and safety of the use of intraoperative image guidance (IIG) in orbital and lacrimal surgery. METHODS: A literature search of the PubMed database was last conducted in November 2023 for English-language original research that assessed the use of any image guidance system in orbital and lacrimal surgery that included at least 5 patients. The search identified 524 articles; 94 were selected for full-text analysis by the panel. A total of 32 studies met inclusion criteria. The panel methodologist assigned a level II rating to 2 studies and a level III rating to 30 studies. No study met the criteria for level I evidence. RESULTS: Procedures reported on were as follows: fracture repair (n = 14), neoplasm and infiltrate biopsy or excision (n = 6), orbital decompression for Graves ophthalmopathy (n = 3), dacryocystorhinostomy (n = 1), and mixed etiology and procedures (n = 8). Four studies used more than one IIG system. One study that met level II evidence criteria compared the outcomes of orbital fracture repair with IIG (n = 29) and without IIG (n = 29). Borderline better outcomes were reported in the IIG group: 2% versus 10% with diplopia (P = 0.039) and 3% versus 10% with enophthalmos (P = 0.065). The other level II study compared the repair of fractures with navigation (n = 20) and without (n = 20). The group in which navigation was used had a measured mean volume reduction of 3.82 cm3 compared with 3.33 cm3 (P = 0.02), and there was a greater measured reduction in enophthalmos in the navigation group of 0.72 mm (P = 0.001). Although the remaining 30 assessed articles failed to meet level II criteria, all alleged a benefit from IIG. No complications were reported. CONCLUSIONS: A small number of comparative studies suggest that there are improved outcomes when IIG is used in orbital fracture repair, but each study suffers from various limitations. No high-quality comparative studies exist for the management of lacrimal surgery, neoplastic disease, or decompression. Complications attributable to the use of IIG have not been identified, and IIG has not been analyzed for cost savings. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
RESUMEN
ABSTRACT Purpose: Increased tarsal platform show (TPS) and decreased brow fat span (BFS) are associated with favorable results in women undergoing cosmetic blepharoplasty. We conducted a study to evaluate the efficacy of upper blepharoplasty with or without a technique (brassiere sutures) to increase TPS and decrease BFS. Methods: This is a prospective, randomized, comparative, case series study of 100 eyelids (50 consecutive women patients) treated with cosmetic upper blepharoplasty performed by a single surgeon. Patients were randomized to receive traditional upper blepharoplasty with a single running suture skin closure versus orbicularis oculi muscle fixation to the periosteum (brassiere sutures) prior to skin closure. Data on patient age, duration of follow-up, complications, and treatment were analyzed. The mean TPS, mean BFS, and mean TPS/BFS ratio were measured at three anatomic landmarks before and after surgery. Results: Fifty-six eyelids (28 patients) were treated with traditional single suture blepharoplasty, and 44 eyelids (22 patients) had brassiere sutures. In both groups, paired t-tests indicate significant differences between preoperative and postoperative evaluations (p<0.05) for eyelid parameters in each location. However, when TPS, BFS, and TPS/BFS ratio were compared between groups with two-way ANOVA, there were no statistically significant differences (p>0.05). Conclusions: Brassiere sutures during upper blepharoplasty and traditional blepharoplasty were associated with postoperative increase in TPS, decrease in BFS, and increase in TPS/BFS, without statistically significant differences between these surgeries.
RESUMO Objetivo: O aumento do TPS (porção pretarsal visível) e a diminuição do BFS (porção preseptal visível) estão associados com resultados favoráveis em mulheres submetidas a blefaroplastia estética. Os autores avaliaram a eficácia da cirurgia de blefaroplastia superior associada ou não à técnica (sutura de brassiere) em aumentar o TPS e diminuir o BFS. Métodos: Estudo prospectivo, comparativo, randomizado de uma série de casos de 100 pálpebras (50 pacientes mulheres) tratados com blefaroplastia superior por um único cirurgião. Os pacientes foram randomizados para ser submetidos a tradicional blefaroplastia superior (com sutura única da pele) ou para realizarem sutura de fixação do músculo orbicular no periósteo (sutura de brassiere) antes da sutura de pele. Foi analisado idade do paciente, tempo de acompanhamento, complicações e tratamento. A média do TPS, BFS e relação TPS/BFS foram medidas antes e depois da cirurgia em três pontos anatômicos. Resultados: Cinquenta e seis pálpebras (28 pacientes) foram submetidas à tradicional blefaroplastia e 44 pálpebras (22 pacientes) fizeram a blefaroplastia superior associado com sutura de brassiere. Em ambos os grupos, os testes t pareados indicam diferenças significativas entre as avaliações pré-operatórias e pós-operatórias (p<0,05) para os parâmetros da pálpebra nos três pontos anatômicos estudados. Contudo, ao comparar os resultados da relação TPS, BFS e TPS/BFS entre os grupos (usando ANOVA bidirecional), não há diferença estatisticamente significante (p>0,05). Conclusão: Suturas de brassiere com blefaroplastia superior e blefaroplastia tradicional foram associadas com um aumento no pós-operatório do TPS, diminuição do BFS, e aumento da relação TPS/BFS, contudo sem diferença estatisticamente significativa entre essas cirurgias.